{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T19:13:41Z","timestamp":1776280421055,"version":"3.50.1"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2018\/31\/B\/NZ7\/00247"],"award-info":[{"award-number":["UMO-2018\/31\/B\/NZ7\/00247"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.pharmthera.2021.107842","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T20:07:55Z","timestamp":1616184475000},"page":"107842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["GPCR oligomerization as a target for antidepressants: Focus on GPR39"],"prefix":"10.1016","volume":"225","author":[{"given":"Katarzyna","family":"Mlyniec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominika","family":"Siod\u0142ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Doboszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"S1","key":"10.1016\/j.pharmthera.2021.107842_bb0005","first-page":"S21","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: G protein-coupled receptors","volume":"176","author":"Alexander","year":"2019","journal-title":"British Journal of Pharmacology"},{"issue":"S1","key":"10.1016\/j.pharmthera.2021.107842_bb0010","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: Catalytic receptors","volume":"176","author":"Alexander","year":"2019","journal-title":"British Journal of Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107842_bb0015","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neuropharm.2008.07.014","article-title":"Chronic antidepressant treatments increase basic fibroblast growth factor and fibroblast growth factor-binding protein in neurons","volume":"55","author":"Bachis","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/bs.pmbts.2019.11.007","article-title":"Prediction and targeting of GPCR oligomer interfaces","volume":"169","author":"Barreto","year":"2020","journal-title":"Progress in Molecular Biology and Translational Science"},{"key":"10.1016\/j.pharmthera.2021.107842_bib401","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.bbrc.2013.10.067","article-title":"Dynamic modulation of FGFR1-5-HT1A heteroreceptor complexes. Agonist treatment enhances participation of FGFR1 and 5-HT1A homodimers and recruitment of \u03b2-arrestin2","volume":"441","author":"Borroto-Escuela","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"October","key":"10.1016\/j.pharmthera.2021.107842_bb0025","first-page":"1","article-title":"Disturbances in the FGFR1-5-HT1A heteroreceptor complexes in the raphe-hippocampal 5-HT system develop in a genetic rat model of depression","volume":"11","author":"Borroto-Escuela","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107842_bb0030","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1021\/acsomega.7b00629","article-title":"Existence of brain 5-HT1A-5-HT2A isoreceptor complexes with antagonistic allosteric receptor-receptor interactions regulating 5-HT1A receptor recognition","volume":"2","author":"Borroto-Escuela","year":"2017","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0035","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbrc.2010.02.078","article-title":"Galanin receptor-1 modulates 5-hydroxtryptamine-1A signaling via heterodimerization","volume":"393","author":"Borroto-Escuela","year":"2010","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbrc.2014.11.112","article-title":"Evidence for the existence of FGFR1\u20135-HT1A heteroreceptor complexes in the midbrain raphe 5-HT system","volume":"456","author":"Borroto-Escuela","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107842_bb0045","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbrc.2015.04.133","article-title":"Enhancement of the FGFR1 signaling in the FGFR1-5-HT1A heteroreceptor complex in midbrain raphe 5-HT neuron systems. Relevance for neuroplasticity and depression","volume":"463","author":"Borroto-Escuela","year":"2015","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0050","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.biopsych.2011.09.012","article-title":"Fibroblast growth factor receptor 1 5-hydroxytryptamine 1A heteroreceptor complexes and their enhancement of hippocampal plasticity","volume":"71","author":"Borroto-Escuela","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107842_bb0055","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.tips.2018.10.007","article-title":"A2AR-D2R Heteroreceptor complexes in cocaine reward and addiction","volume":"39","author":"Borroto-Escuela","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107842_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2017.11.004","article-title":"Studying GPCR pharmacology in membrane microdomains: Fluorescence correlation spectroscopy comes of age","volume":"39","author":"Briddon","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107842_bb0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tips.2017.10.010","article-title":"Single-molecule imaging of GPCR interactions","volume":"39","author":"Calebiro","year":"2018","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0070","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1039\/C7FD00192D","article-title":"Exploring oligomeric state of the serotonin 1A receptor utilizing photobleaching image correlation spectroscopy: Implications for receptor function","volume":"207","author":"Chakraborty","year":"2018","journal-title":"Faraday Discussions"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107842_bb0075","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1021\/acschemneuro.8b00665","article-title":"Attenuation of oxytocin and serotonin 2A receptor signaling through novel Heteroreceptor formation","volume":"10","author":"Chru\u015bcicka","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0080","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3389\/fphar.2019.00060","article-title":"Fibroblast growth factors in depression","volume":"10","author":"Deng","year":"2019","journal-title":"Frontiers in Pharmacology"},{"issue":"48","key":"10.1016\/j.pharmthera.2021.107842_bb0085","doi-asserted-by":"crossref","first-page":"18109","DOI":"10.1074\/jbc.RA119.009253","article-title":"Rare-variant pathogenicity triage and inclusion of synonymous variants improves analysis of disease associations of orphan G protein-coupled receptors","volume":"294","author":"Dershem","year":"2019","journal-title":"Journal of Biological Chemistry"},{"issue":"1601","key":"10.1016\/j.pharmthera.2021.107842_bb0090","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1098\/rstb.2011.0361","article-title":"Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT 1A receptors and SERT","volume":"367","author":"Descarries","year":"2012","journal-title":"Philosophical Transactions of the Royal Society, B: Biological Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/BF02245592","article-title":"Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants","volume":"121","author":"Detke","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0100","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3682752","article-title":"Zinc in the monoaminergic theory of depression: Its relationship to neural plasticity","author":"Doboszewska","year":"2017","journal-title":"Neural Plasticity"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0105","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im1810s52","article-title":"Fluorescence resonance energy transfer: Techniques for measuring molecular conformation and molecular proximity","volume":"57","author":"Edidin","year":"2003","journal-title":"Current Protocols in Immunology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0110","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.biopsych.2012.03.003","article-title":"Antidepressant effects of fibroblast growth Factor-2 in behavioral and cellular models of depression","volume":"72","author":"Elsayed","year":"2012","journal-title":"Biological Psychiatry"},{"issue":"43","key":"10.1016\/j.pharmthera.2021.107842_bb0115","doi-asserted-by":"crossref","first-page":"15506","DOI":"10.1073\/pnas.0406788101","article-title":"Dysregulation of the fibroblast growth factor system in major depression","volume":"101","author":"Evans","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107842_bb0120","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nchembio0309-131","article-title":"Building a new conceptual framework for receptor heteromers","volume":"5","author":"Ferr\u00e9","year":"2009","journal-title":"Nature Chemical Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107842_bb0125","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nn.2216","article-title":"FGF acts as a co-transmitter through adenosine A2A receptor to regulate synaptic plasticity","volume":"11","author":"Flajolet","year":"2008","journal-title":"Nature Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107842_bb0130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Molecular Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107842_bb0135","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nbt0502-473","article-title":"Protein detection using proximity-dependent DNA ligation assays","volume":"20","author":"Fredriksson","year":"2002","journal-title":"Nature Biotechnology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12859-018-2392-y","article-title":"Uncovering new disease indications for G-protein coupled receptors and their endogenous ligands","volume":"19","author":"Freudenberg","year":"2018","journal-title":"BMC Bioinformatics"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107842_bb0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bpj.2010.12.3692","article-title":"Organization of Higher-Order Oligomers of the Serotonin1A receptor explored utilizing Homo-FRET in live cells","volume":"100","author":"Ganguly","year":"2011","journal-title":"Biophysical Journal"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107842_bb0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nature Reviews Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2021.107842_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2008.07.011","article-title":"Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice","volume":"593","author":"G\u00fcnther","year":"2008","journal-title":"European Journal of Pharmacology"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107842_bb0160","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41583-019-0221-6","article-title":"The future of rodent models in depression research","volume":"20","author":"Gururajan","year":"2019","journal-title":"Nature Reviews Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0165","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.sbi.2020.03.004","article-title":"Beyond structure: Emerging approaches to study GPCR dynamics","volume":"63","author":"Gusach","year":"2020","journal-title":"Current Opinion in Structural Biology"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107842_bb0170","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications Alexander","volume":"16","author":"Hauser","year":"2019","journal-title":"Nature Reviews Drug Discovery"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2021.107842_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cell.2017.11.033","article-title":"Pharmacogenomics of GPCR drug targets","volume":"172","author":"Hauser","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107842_bb0180","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ajhg.2013.04.015","article-title":"Sequence kernel association tests for the combined effect of rare and common variants","volume":"92","author":"Ionita-Laza","year":"2013","journal-title":"The American Journal of Human Genetics"},{"issue":"6712","key":"10.1016\/j.pharmthera.2021.107842_bb0185","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/25348","article-title":"GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2","volume":"396","author":"Jones","year":"1998","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107842_bb0190","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.bbamcr.2008.02.021","article-title":"Stimulation- and palmitoylation-dependent changes in oligomeric conformation of serotonin 5-HT1A receptorsi","volume":"1783","author":"Kobe","year":"2008","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0195","first-page":"1","article-title":"GCRDb: A G-protein-coupled receptor database","volume":"2","author":"Kolakowski","year":"1994","journal-title":"Receptors and Channels"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0200","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/14728222.2018.1452912","article-title":"Interplay between the key proteins of serotonin system in SSRI antidepressants efficacy","volume":"22","author":"Kulikov","year":"2018","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0205","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1124\/pr.112.006536","article-title":"Physiology, signaling, and pharmacology of galanin peptides and receptors: Three decades of emerging diversity","volume":"67","author":"Lang","year":"2015","journal-title":"Pharmacological Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107842_bb0210","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2174\/138161209787315602","article-title":"Multivalent-based drug design applied to serotonin 5-HT4 receptor oligomers","volume":"15","author":"Lezoualc\u2019h","year":"2009","journal-title":"Current Pharmaceutical Design"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0215","first-page":"379","article-title":"Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane","volume":"59","author":"\u0141ukasiewicz","year":"2007","journal-title":"Pharmacological Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0220","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jnc.13582","article-title":"Dopamine D 2 and serotonin 5-HT 1A receptor interaction in the context of the effects of antipsychotics - in vitro studies","volume":"137","author":"\u0141ukasiewicz","year":"2016","journal-title":"Journal of Neurochemistry"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2021.107842_bb0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0165-0327(99)00011-7","article-title":"Lower serum zinc in major depression in relation to changes in serum acute phase proteins","volume":"56","author":"Maes","year":"1999","journal-title":"Journal of Affective Disorders"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107842_bb0230","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1021\/acschemneuro.5b00023","article-title":"Cartography of 5-HT 1A and 5-HT 2A receptor subtypes in prefrontal cortex and its projections","volume":"6","author":"Mengod","year":"2015","journal-title":"ACS Chemical Neuroscience"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107842_bb0235","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1007\/s00429-015-1180-y","article-title":"Galanin (1\u201315) enhances the antidepressant effects of the 5-HT1A receptor agonist 8-OH-DPAT: Involvement of the raphe-hippocampal 5-HT neuron system","volume":"221","author":"Mill\u00f3n","year":"2016","journal-title":"Brain Structure and Function"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107842_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu064","article-title":"A role for galanin N-terminal fragment (1-15) in anxiety-and depression-related behaviors in Ra","volume":"18","author":"Mill\u00f3n","year":"2015","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2174\/1570159X13666150115220617","article-title":"Zinc in the glutamatergic theory of depression","volume":"13","author":"Mlyniec","year":"2015","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2013.12.001","article-title":"The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims","volume":"79","author":"M\u0142yniec","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.brainresbull.2015.04.005","article-title":"Investigation of the GPR39 zinc receptor following inhibition of monoaminergic neurotransmission and potentialization of glutamatergic neurotransmission","volume":"115","author":"M\u0142yniec","year":"2015","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0260","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbr.2015.03.053","article-title":"Study of antidepressant drugs in GPR39 (zinc receptor\u2212\/\u2212) knockout mice, showing no effect of conventional antidepressants, but effectiveness of NMDA antagonists","volume":"287","author":"M\u0142yniec","year":"2015","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107842_bib403","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2016.05.007","article-title":"Potential antidepressant-like properties of the TC G-1008, a GPR39 (zinc receptor) agonist","volume":"201","author":"M\u0142yniec","year":"2016","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2021.107842_bib404","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X19666210225153404","article-title":"Interaction between zinc, GPR39, BDNF and neuropeptides in depression","author":"Mlyniec","year":"2021","journal-title":"Current Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0265","doi-asserted-by":"crossref","first-page":"108070","DOI":"10.1016\/j.neuropharm.2020.108070","article-title":"Existence of FGFR1-5-HT1AR heteroreceptor complexes in hippocampal astrocytes. Putative link to 5-HT and FGF2 modulation of hippocampal gamma oscillations","volume":"170","author":"Narv\u00e1ez","year":"2020","journal-title":"Neuropharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107842_bb0270","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cns.12247","article-title":"Interplay between serotonin 5-HT 1A and 5-HT 7 receptors in depressive disorders","volume":"20","author":"Naumenko","year":"2014","journal-title":"CNS Neuroscience & Therapeutics"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107842_bb0275","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.tins.2012.08.004","article-title":"Balance of brain oxytocin and vasopressin: Implications for anxiety, depression, and social behaviors","volume":"35","author":"Neumann","year":"2012","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0280","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.euroneuro.2016.11.013","article-title":"Inverse agonists \u2013 What do they mean for psychiatry?","volume":"27","author":"Nutt","year":"2017","journal-title":"European Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/bmb\/lds004","article-title":"The neurobiology of depression","volume":"101","author":"Palazidou","year":"2012","journal-title":"British Medical Bulletin"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0290","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.bbr.2009.03.027","article-title":"Memory time-course: mRNA 5-HT1A and 5-HT7 receptors","volume":"202","author":"Perez-Garcia","year":"2009","journal-title":"Behavioural Brain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1124\/pr.59.1.5","article-title":"International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the Recognition and Nomenclature of G Protein-Coupled Receptor Heteromultimers","volume":"59","author":"Pin","year":"2007","journal-title":"Pharmacological Reviews"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0300","doi-asserted-by":"crossref","first-page":"16312","DOI":"10.1038\/s41598-019-52540-8","article-title":"Differential allosteric modulation within dopamine D2R - neurotensin NTS1R and D2R - serotonin 5-HT2AR receptor complexes gives bias to intracellular calcium signalling","volume":"9","author":"Plach","year":"2019","journal-title":"Scientific Reports"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107842_bb0305","first-page":"2486","article-title":"Heterodimerization of serotonin receptors 5-HT1A and 5-HT7 differentially regulates receptor signalling and trafficking","volume":"125","author":"Renner","year":"2012","journal-title":"Journal of Cell Science"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107842_bb0310","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tips.2005.03.001","article-title":"Emerging role of the FGF system in psychiatric disorders","volume":"26","author":"Riva","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2021.107842_bb0315","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1073\/pnas.0906695106","article-title":"Rescue of defective G protein - coupled receptor function in vivo by intermolecular cooperation","volume":"107","author":"Rivero-M\u00fcller","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107842_bb0320","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0006-8993(03)02832-4","article-title":"Autoradiographic analyses of 5-HT1A and 5-HT2A receptors after social isolation in mice","volume":"980","author":"Schiller","year":"2003","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107842_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01489-1","article-title":"Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation","volume":"8","author":"Scholler","year":"2017","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2021.107842_bib402","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.brainresbull.2021.02.003","article-title":"Interaction between zinc, the GPR39 zinc receptor and the serotonergic system in depression","volume":"170","author":"Siod\u0142ak","year":"2021","journal-title":"Brain Research Bulletin"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107842_bb0330","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S1734-1140(13)71512-3","article-title":"Zinc as a marker of affective disorders","volume":"65","author":"Siwek","year":"2013","journal-title":"Pharmacological Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0335","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.pharep.2017.01.030","article-title":"Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant","volume":"69","author":"Sowa-Ku\u0107ma","year":"2017","journal-title":"Pharmacological Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0340","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0345","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jad.2018.11.003","article-title":"Long-lasting antidepressant-like activity of the GPR39 zinc receptor agonist TC-G 1008","volume":"245","author":"Starowicz","year":"2019","journal-title":"Journal of Affective Disorders"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0350","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2018.00040","article-title":"Repeated clozapine increases the level of serotonin 5-HT1AR Heterodimerization with 5-HT2A or dopamine D2 receptors in the mouse cortex","volume":"11","author":"Szlachta","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0355","article-title":"Purinergic transmission in depressive disorders","volume":"107821","author":"Szopa","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107842_bb0360","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pharmthera.2011.10.007","article-title":"A new approach for studying GPCR dimers: Drug-induced inactivation and reactivation to reveal GPCR dimer function in vitro, in primary culture, and in vivo","volume":"133","author":"Teitler","year":"2012","journal-title":"Pharmacology & Therapeutics"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107842_bb0365","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.bbadis.2015.09.003","article-title":"The zinc binding receptor GPR39 interacts with 5-HT1A and GalR1 to form dynamic heteroreceptor complexes with signaling diversity","volume":"1852","author":"Tena-Campos","year":"2015","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2021.107842_bb0370","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s12035-015-9153-y","article-title":"Zinc is involved in depression by modulating G protein-coupled receptor Heterodimerization","volume":"53","author":"Tena-Campos","year":"2016","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0375","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.sbi.2019.04.005","article-title":"Computational prediction of GPCR oligomerization","volume":"55","author":"Townsend-Nicholson","year":"2019","journal-title":"Current Opinion in Structural Biology"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainres.2008.05.088","article-title":"Antidepressant-like effects of Intracerebroventricular FGF2 in rats","volume":"1224","author":"Turner","year":"2008","journal-title":"Brain Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0385","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.biopsych.2012.05.025","article-title":"Fibroblast growth Factor-2: An endogenous antidepressant and anxiolytic molecule?","volume":"72","author":"Turner","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107842_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01240","article-title":"Heteromerization modulates mu opioid receptor functional properties in vivo","volume":"9","author":"Ugur","year":"2018","journal-title":"Frontiers in Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2021.107842_bb0395","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10719-008-9187-8","article-title":"Specific oligomerization of the 5-HT1A receptor in the plasma membrane","volume":"26","author":"Woehler","year":"2009","journal-title":"Glycoconjugate Journal"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107842_bb0400","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/10799890701506147","article-title":"Isolation of Zn 2+ as an endogenous agonist of GPR39 from fetal bovine serum","volume":"27","author":"Yasuda","year":"2007","journal-title":"Journal of Receptors and Signal Transduction"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:13:24Z","timestamp":1759011204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":84,"alternative-id":["S0163725821000449"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107842","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GPCR oligomerization as a target for antidepressants: Focus on GPR39","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107842"}}